Nexavar Data to Be Presented at American Society of Clinical Oncology Annu... (rse reactions temporary treatment interr...)

Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting

Date:5/18/2011

rse reactions, temporary treatment interruption, dose modification, or permanent discontinuation of Nexavar should be considered. Temporary interruption of Nexavar therapy is recommended in patients undergoing major surgical procedures

Elevations in serum lipase and reductions in serum phosphate of unknown etiology have been associated with Nexavar. Caution is recommended when administering Nexavar with compounds that are metabolized/eliminated predominantly by the UGT1A9 pathway, UGT1A1 pathway (eg, irinotecan), doxorubicin, docetaxel, fluorouracil, and substrates of CYP2B6 and CYP2C8, and CYP3A4 inducers. Concomitant use of carboplatin and paclitaxel with sorafenib resulted in an increase in paclitaxel exposure and an increase in Nexavar exposure. Patients taking concomitant warfarin should be monitored regularly for changes in prothrombin time, INR, or clinical bleeding episodes. Nexavar exposure decreases when coadministered with oral neomycin. Effects of other antibiotics on Nexavar pharmacokinetics have not been studied

Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in unresectable HCC, respectively, were: diarrhea (55% vs 25%), fatigue (46% vs 45%), abdominal pain (31% vs 26%), weight loss (30% vs 10%), anorexia (29% vs 18%), nausea (24% vs 20%), and hand-foot skin reaction (21% vs 3%). Grade 3/4 adverse reactions were 45% vs 32%

Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in advanced RCC, respectively, were: diarrhea (43% vs 13%), rash/desquamation (40% vs 16%), fatigue (37% vs 28%), hand-foot skin reaction (30% vs 7%), alopecia (27% vs 3%), and nausea (23% vs 19%). Grade 3/4 adverse reactions were 38% vs 28%

During postapproval use of Nexavar, the following adverse drug reactions have been identified: angioedema and drug-induced hepatitis, including reports of hepatic failure and death

For information about Nexavar includin
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
2. Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
3. Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
4. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
5. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
6. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
7. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
8. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
9. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
10. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
11. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study

Post Your Comments:

(Date:6/18/2013)... -- New-generation electronic designs are focused on rugged ... circuitry is increasing the number of functions it ... performs at. Connecting cables from the active elements ... as cameras or detectors, must be small, flexible ... custom cable designs for high-quality signal and EMI ...

(Date:6/18/2013)... And EMERYVILLE, Calif. , June ... final results today from a Phase 2/3 clinical ... demonstrating a statistically significant improvement in levodopa-induced dyskinesia ... week 8 versus placebo in the Unified Dyskinesia ... formulation of amantadine intended for once-nightly administration that ...

(Date:6/18/2013)... 18, 2013 Polymer Technology Systems, Inc. ... Health Group to integrate the CardioChek ® ... administered by health systems across the country. The ... and distributed through Hanson Medical Systems , ... cholesterol, LDL cholesterol, triglycerides, and glucose. ...

Breaking Medicine Technology:Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5 Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6 Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2 Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3

[0] Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility [0] Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease [0] Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients

... WOODLANDS, Texas, Aug. 10, 2011 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... trial of LX1031 in patients with non-constipating ... in the August 2011 edition of the journal ...

... Environmental testing and monitoring programs are essential ... understand industrial sterilization and contamination control procedures to bring ... In attempting to meet regulatory demands from ... Pharmacopoeia, the greatest challenge for medical device and pharmaceutical ...

Cached Medicine Technology:Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology 2 Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology 3 "Environmental Monitoring and Certification in Controlled Environments: Meeting Regulations and Achieving Effective Microbial Control for Pharmaceutical and Medical Device Manufacturers" - New White Paper from Microtest Laboratories 2

Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology "Environmental Monitoring and Certification in Controlled Environments: Meeting Regulations and Achieving Effective Microbial Control for Pharmaceutical and Medical Device Manufacturers" - New White Paper from Microtest Laboratories

(Date:6/19/2013)... CO (PRWEB) June 19, 2013 ... marketing company for coaches, announced today its affiliation ... means CoachingWebsites will offer exclusive websites and marketing ... partnerships. , “This new partnership with Active Intelligence ... their business to its fullest,” says Greer Van ...

(Date:6/19/2013)... 2013 The Mesothelioma Victims Center ... of the 2500 to 3000 citizens, who will be ... this year, about one third will be US Navy ... with this asbestos exposure form of cancer, or their ... to the nations most skilled mesothelioma compensation settlement attorneys, ...

(Date:6/19/2013)... Middle market merger and acquisition (M&A) activity ... cash rich buyers seek to place their capital in ... transactions have a good deal in common. The acquirer ... and quality of the target company’s earnings. Potential risks ... diligence involves a middle market company, whose value consists ...

(Date:6/18/2013)... 19, 2013 oBand Surgery Centers, a ... holding complimentary weight loss seminars in Los Angeles this ... be accessed at their official website. oBand Surgery Centers ... time. Their highly skilled panel of surgeons and dedicated ... , A senior executive working with oBand Surgery Centers ...

(Date:6/18/2013)... Philadelphia, PA, June 19, 2013 Recent studies ... coverage of bullying-related suicide among young people, led ... to assemble an expert panel to focus on ... about the complex relationship between youth involvement in ... Bullying among youth is a significant public health ...

Breaking Medicine News(10 mins):Health News:CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC 2 Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 2 Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 3 Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 2 Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 3 Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2 Health News:Bullying and suicide among youth is a public health problem 2

[0] CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC [0] Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation [0] Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company [0] oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June [0] Bullying and suicide among youth is a public health problem

... May 11 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... worldwide announced today its selected unaudited,financial results for the first ... Highlights for First Quarter 2009, -- First ... 53.5% over the first ...

... Trust Incorporated (NYSE: HR ) today announced its ... 2009. This dividend, in the amount of $0.385 per ... record on May 22, 2009. The total dividend of ... operations determined in accordance with GAAP. The Company,s cash ...

... Health Care Costs Over Next Ten Years, Provides Significant ... Year WASHINGTON, May 11 Today, key stakeholders in ... House to announce their commitment to achieving a sharp ... to prioritize preventive care, manage chronic illnesses, curtail unnecessary ...

... will be lethality of infection going forward, experts say , , ... epidemic does have pandemic potential and is likely to be ... of its spread, a new expert analysis concludes. , The ... unreported -- swine flu infections in Mexico, the outbreak,s epicenter, ...

... Call on May 14, 2009 NEW HAVEN, Conn., May 11 ... announced financial results for the first quarter of 2009. , ... $4.3 million, or $0.54 per share, for the quarter ended March ... $1.14 per share, for the same 2008 period. Weighted-average common ...

... prominently featured on the HRS 2009 programST. LOUIS, May ... said today that the Heart Rhythm 2009 formal program ... Niobe system is either featured or discussed regarding the ... efficacy data on the use of Stereotaxis, partnered magnetic ...

Mindray Announces First Quarter 2009 Financial Results Healthcare Realty Trust Announces First Quarter Dividend Kaine Lauds President Obama's Agreement With Health Care Industry Groups to Reduce Health Care Costs Study Supports Swine Flu's Pandemic Potential Vion Pharmaceuticals Reports 2009 First Quarter Results Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009

Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....

VascoStim 2F are bipolar temporary pacing leads to be used in conjunction with thermodilution catheters with implemented paceport-channel....

The Aescula LV left-heart lead is a stylet-driven, silicone insulated lead with a titanium nitride (TiN) coated platinum-iridium electrode....

Medicine Products:

VascoStim 2/5F J VascoStim 2/5F S VascoStim 2F Aescula LV Left-Heart Lead